SOLICITATION NOTICE
99 -- Proteomics of Human Plasma and/or Serum
- Notice Date
- 5/20/2019
- Notice Type
- Combine Synopsis/Solicitation
- NAICS
- 541714
— Research and Development in Biotechnology (except Nanobiotechnology)
- Contracting Office
- 4041 Powder Mill Road Beltsville MD 20705
- ZIP Code
- 20705
- Solicitation Number
- FDAIDIQ1210078
- Response Due
- 6/3/2019
- Point of Contact
- Telisha Wilson , Contract Specialist , Phone 2404027572
- E-Mail Address
-
telisha.wilson@fda.hhs.gov
- Small Business Set-Aside
- N/A
- Description
- Document Type Request for Proposal-IDIQ Solicitation Number RFQ 1210078 Subject Proteomics of Human Plasma and/or Serum Questions Due May 24, 2019 at 10am Proposal Due June 03, 2019 at 10am NIACS Code 541714 Research and Development in Biotechnology (except Nanobiotechnology). PART I SECTION B-SUPPLIES OR SERVICES AND PRICES/COST B.1 DESCRIPTIVE OF SERVICES The FDA has a mission to protect public health by assuring the safety, efficacy, and security of human and veterinary drugs, biological products, medical devices, our nation's food supply, cosmetics, and products that emit radiation. In addition, FDA is responsible for facilitating innovations that make medicines more effective, safer, and more affordable. To accomplish these goals, FDA has stimulated advancement of regulatory science, which is defined as "the science of developing new tools, standards, and approaches to assess the safety, efficacy, quality, and performance of all FDA regulated products." Blood plasma and serum contains thousands of proteins and specific changes in the plasma or serum "proteome" (which is the entire set of proteins produced by all the genes in the body) might reflect changes in response to both drug exposure and response in different cells and tissues of the body. Successful detection and quantitation of tissue-specific proteins by innovative technologies has positioned plasma or serum proteomics as a promising candidate for non-invasive biomarker discovery. Therefore, it is likely that proteomic analysis of human plasma or serum might identify novel biomarkers and/or a proteomic signature of drug exposure and response. NOTE: THIS NOTICE WAS NOT POSTED TO FEDBIZOPPS ON THE DATE INDICATED IN THE NOTICE ITSELF (20-MAY-2019); HOWEVER, IT DID APPEAR IN THE FEDBIZOPPS FTP FEED ON THIS DATE. PLEASE CONTACT 877-472-3779 or fbo.support@gsa.gov REGARDING THIS ISSUE.
- Web Link
-
Link To Document
(https://www.fbo.gov/spg/HHS/FDA/DCASC/FDAIDIQ1210078/listing.html)
- Record
- SN05317219-F 20190522/190520230030 (fbodaily.com)
- Source
-
FedBizOpps Link to This Notice
(may not be valid after Archive Date)
| FSG Index | This Issue's Index | Today's FBO Daily Index Page |